Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma

NCT00287222 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Bevacizumab
DRUG: Erlotinib

Sponsor

University of Arkansas

Collaborators

[object Object]